Ranbaxy launches GSK’s blockbuster drug in US
Has six-month exclusive marketing right to anti-herpes Valtrex. In a move that will help Ranbaxy boost its revenues from the US in the next six months, the company has launched the generic version of GlaxoSmithKline’s blockbuster medicine Valtrex in the United States.
If you enjoyed this post, make sure you subscribe to my RSS feed!
